For: | Yazici O, Şendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014; 20(22): 6716-6724 [PMID: 24944464 DOI: 10.3748/wjg.v20.i22.6716] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i22/6716.htm |
Number | Citing Articles |
1 |
Sattva S Neelapu, Sherry Adkins, Stephen M Ansell, Joshua Brody, Mitchell S Cairo, Jonathan W Friedberg, Justin P Kline, Ronald Levy, David L Porter, Koen van Besien, Michael Werner, Michael R Bishop. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. Journal for ImmunoTherapy of Cancer 2020; 8(2): e001235 doi: 10.1136/jitc-2020-001235
|
2 |
Ivan Noreña, Mario Fernández-Ruiz, José María Aguado. Viral infections in the biologic therapy era. Expert Review of Anti-infective Therapy 2018; 16(10): 781 doi: 10.1080/14787210.2018.1521270
|
3 |
Sarah L. Martindale, Robin A. Hurley, Katherine H. Taber. Neurobiology and Neuroimaging of Chronic Hepatitis C Virus: Implications for Neuropsychiatry. The Journal of Neuropsychiatry and Clinical Neurosciences 2017; 29(4): A6 doi: 10.1176/appi.neuropsych.17080163
|
4 |
Cristina Gutierrez, Colleen McEvoy, Laveena Munshi, R. Scott Stephens, Michael E. Detsky, Joseph L. Nates, Stephen M. Pastores. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Critical Care Medicine 2020; 48(1): 10 doi: 10.1097/CCM.0000000000004087
|
5 |
Kenneth V. I. Rolston. Infections in Cancer Patients with Solid Tumors: A Review. Infectious Diseases and Therapy 2017; 6(1): 69 doi: 10.1007/s40121-017-0146-1
|
6 |
Harrys A. Torres, Jeff Hosry, Parag Mahale, Minas P. Economides, Ying Jiang, Anna S. Lok. Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology 2018; 67(1): 36 doi: 10.1002/hep.29344
|
7 |
Emre Akar, Mehmet Haluk Yücel, Tunahan Şahin, Deniz Tural. Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy. Tumori Journal 2019; 105(6): NP72 doi: 10.1177/0300891619840279
|
8 |
Hiroki Kaneko, Yoshinori Ozono, Hisayoshi Iwakiri, Hiroshi Hatada, Naomi Uchiyama, Yuri Komaki, Kenichi Nakamura, Satoru Hasuike, Kenji Nagata, Hiroshi Kawakami. Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness. Clinical Journal of Gastroenterology 2024; 17(3): 505 doi: 10.1007/s12328-024-01944-9
|
9 |
Cha Young Kim, Bo Ra Kim, Sang Soo Lee, Dae-Hong Jeon, Chang Min Lee, Wan Soo Kim, Hyun Chin Cho, Jin Joo Kim, Jae Min Lee, Hong Jun Kim, Chang Yoon Ha, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok-Jae Lee. Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma. Medicine 2017; 96(2): e5844 doi: 10.1097/MD.0000000000005844
|
10 |
Raffaele Bruno, Valentina Zuccaro, Carmine Pinto, Massimo Puoti, Giovanni Battista Gaeta, Anna Pagani, Gloria Taliani, Fausto Baldanti, Saverio Cinieri, Paolo Pedrazzoli. Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). Seminars in Oncology 2018; 45(5-6): 259 doi: 10.1053/j.seminoncol.2018.07.004
|
11 |
Meinolf Suttorp, Andrea Webster Carrion, Nobuko Hijiya. Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations. Journal of Clinical Medicine 2021; 10(18): 4056 doi: 10.3390/jcm10184056
|
12 |
Claudia Bozza, Marika Cinausero, Donatella Iacono, Fabio Puglisi. Hepatitis B and cancer: A practical guide for the oncologist. Critical Reviews in Oncology/Hematology 2016; 98: 137 doi: 10.1016/j.critrevonc.2015.10.017
|
13 |
Dan Pu, Liyuan Yin, Yuwen Zhou, Wen Li, Lin Huang, Liang Cai, Qinghua Zhou. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer. Medicine 2020; 99(5): e19013 doi: 10.1097/MD.0000000000019013
|
14 |
Omar Abdel-Rahman, Hesham ElHalawani, Mona Fouad. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opinion on Drug Safety 2015; 14(10): 1507 doi: 10.1517/14740338.2015.1085969
|
15 |
|
16 |
J. Steuart Richards, Sharon Dowell, Mercedes Quinones. Comorbidity in Rheumatic Diseases. 2017; : 345 doi: 10.1007/978-3-319-59963-2_17
|
17 |
Yishai Ofran, Martin S. Tallman, Jacob M. Rowe. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood 2016; 128(4): 488 doi: 10.1182/blood-2016-01-635060
|
18 |
C. Resteghini, S. Cavalieri, D. Galbiati, R. Granata, S. Alfieri, C. Bergamini, P. Bossi, L. Licitra, L.D. Locati. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Practice & Research Clinical Endocrinology & Metabolism 2017; 31(3): 349 doi: 10.1016/j.beem.2017.04.012
|
19 |
Lucia Diella, Davide Fiore Bavaro, Giacomo Loseto, Crescenza Pasciolla, Carla Minoia, Daniela Di Gennaro, Alessandra Belati, Maria Stella De Candia, Francesco Di Gennaro, Annalisa Saracino, Attilio Guarini. Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections. Expert Review of Hematology 2023; 16(4): 267 doi: 10.1080/17474086.2023.2192918
|
20 |
Katharina Lankes, Gheorghe Hundorfean, Thomas Harrer, Ansgar J. Pommer, Abbas Agaimy, Irena Angelovska, Azadeh Tajmir-Riahi, Jonas Göhl, Gerold Schuler, Markus F. Neurath, Werner Hohenberger, Lucie Heinzerling. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. OncoImmunology 2016; 5(6): e1128611 doi: 10.1080/2162402X.2015.1128611
|
21 |
Hyun Mi Kwon, Kichul Shin, Jin Young Moon, Shin-Seok Lee, Won Tae Chung, Jisoo Lee, Sang-Heon Lee, Seong-Wook Kang, Chang Hee Suh, Seung-Jae Hong, Ran Song, Jung-Yoon Choe, Yeong Wook Song. Transaminase Changes in Korean Rheumatoid Arthritis Patients with Chronic Hepatitis C after Biologic Therapy. Journal of Rheumatic Diseases 2018; 25(2): 108 doi: 10.4078/jrd.2018.25.2.108
|
22 |
Tatiana Zorina, Alexis Styche. Infection and Cancer: Bi-Directorial Interactions. 2015; : 295 doi: 10.1007/978-3-319-20669-1_14
|
23 |
T. Feldkamp, O. Witzke. Infektiöse Komplikationen der immunsuppressiven Therapie. Der Nephrologe 2015; 10(1): 38 doi: 10.1007/s11560-014-0908-7
|
24 |
Yutaka Tsutsumi, Shinichi Ito, Souichi Shiratori, Takanori Teshima. Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection. Cancers 2023; 15(10): 2852 doi: 10.3390/cancers15102852
|
25 |
Jun Cheng, Jinjin Pan, Dongmei Zhao, Xuejiao Ma, Qiulin Sun, Jiabin Li. HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report. International Medical Case Reports Journal 2024; : 121 doi: 10.2147/IMCRJ.S444521
|
26 |
Delphine Rea. Chronic Myeloid Leukemia. Hematologic Malignancies 2016; : 71 doi: 10.1007/978-3-319-33198-0_5
|
27 |
Sharav A. Desai, Vipul P. Patel, Kunal P. Bhosle, Sandip D. Nagare, Kirti C. Thombare. The tumor microenvironment: shaping cancer progression and treatment response. Journal of Chemotherapy 2025; 37(1): 15 doi: 10.1080/1120009X.2023.2300224
|
28 |
Kosuke Sato, Jun Inoue, Eiji Kakazu, Masashi Ninomiya, Tomoaki Iwata, Akitoshi Sano, Mio Tsuruoka, Atsushi Masamune. Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia. Clinical Journal of Gastroenterology 2021; 14(4): 1221 doi: 10.1007/s12328-021-01432-4
|
29 |
Murad Kiyas oglu Mamedov, T. N Mamedova, Yu. A. Akhmedov. PERSPECTIVES OF INVESTIGATION OF ONCOLOGICAL ASPECTS OF INFECTION CAUSED WITH HEPATITIS C VIRUS. Russian Journal of Oncology 2019; 24(1-2): 39 doi: 10.18821/1028-9984-2019-24-1-2-39-44
|
30 |
Mohamoud A. Ali, Waqas Z. Kayani, Bradley M. Linzie, Gopal V. Punjabi, James B. Wetmore. Myopericarditis in a patient with hepatitis C and cryoglobulinemic renal disease. Clinical Case Reports 2017; 5(5): 616 doi: 10.1002/ccr3.788
|